Polymyalgia Rheumatica

At every initial PMR assessment, ask specifically about new localized headache, scalp tenderness, temporal artery tenderness or reduced pulse, visual change or visual loss, and other ischemia-related symptoms. These are cranial GCA features used in FDA-reviewed GCA trial eligibility criteria and should trigger urgent GCA-directed assessment rather than an assumption of uncomplicated PMR. accessdata fdaaccessdata fda125276Orig1s112 | FDA

Check for a PMR-GCA overlap even when the presenting complaint is proximal stiffness: PMR features are present in 40%-60% of patients with GCA at diagnosis, and approximately 22% of patients with PMR have concurrent GCA reported in referral literature. AHA Journals+1AHA JournalsMedium- and Large-Vessel Vasculitis | CirculationScienceDirectConcurrent baseline diagnosis of giant cell arteritis and polymyalgia rheumatica – A systematic review and meta-analysis A patient with visual symptoms, new headache, scalp tenderness, or fever should not be managed solely with a low-dose PMR glucocorticoid regimen. accessdata fda+1accessdata fda125276Orig1s112 | FDArheumatologyPolymyalgia Rheumatica | American College of Rheumatology

Age helps frame the differential but does not establish the diagnosis. PMR is a disorder of older adults; age younger than 50 years is an atypical feature that should intensify evaluation for an alternative explanation of polymyalgic symptoms. ScienceDirect+1ScienceDirectCurrent diagnosis and treatment of polymyalgia rheumaticaScienceDirectPolymyalgia Rheumatica - an overview

Use the 2012 EULAR/ACR provisional classification criteria as a structured aid in patients with suspected PMR; the ACR lists these criteria as PMR classification criteria. rheumatologyrheumatologyACR-Endorsed Criteria They are not a definitive diagnostic test: retrospective validation work found that a modified version can identify valid PMR diagnoses in surveys, while the broader diagnostic literature emphasizes a polymyalgic syndrome that may arise from PMR or another disease. ScienceDirect+1ScienceDirectCurrent diagnosis and treatment of polymyalgia rheumaticaOxford AcademicValidity of polymyalgia rheumatica diagnoses and ...

Obtain ESR and CRP at baseline and interpret them as part of a syndrome-level assessment, not as standalone proof. In a pivotal GCA program, historical ESR at least 50 mm/hour or CRP at least 2.45 mg/dL was used as an inflammatory entry criterion for GCA, underscoring why elevated acute-phase reactants in a patient with polymyalgic symptoms should also prompt an explicit GCA screen. accessdata fdaaccessdata fda125276Orig1s112 | FDA ESR below 40 mm/hour or above 100 mm/hour is an atypical PMR pattern that warrants renewed attention to alternatives. ScienceDirectScienceDirectPolymyalgia Rheumatica - an overview

The principal diagnostic safeguard is deliberate consideration of inflammatory rheumatic disease, systemic infection, and malignancy. Rheumatoid arthritis and other inflammatory articular diseases can present with a polymyalgic syndrome, while systemic infections and malignancy can mimic PMR. ScienceDirect+1ScienceDirectCurrent diagnosis and treatment of polymyalgia rheumaticaScienceDirectPolymyalgia Rheumatica - an overview Limited or asymmetric involvement of the usual sites, age under 50 years, and discordant ESR values are practical flags to pause before initiating a prolonged PMR treatment course. ScienceDirectScienceDirectPolymyalgia Rheumatica - an overview

Musculoskeletal ultrasound can increase the specificity of the 2012 EULAR/ACR criteria when distinguishing PMR from rheumatoid arthritis and other inflammatory articular diseases. ScienceDirectScienceDirectPolymyalgia Rheumatica - an overview Reserve PET/CT for selected unresolved cases or when another process remains plausible; it can assist in differentiating PMR/GCA from mimics but entails substantial cost, with an average Medicare reimbursement cited at approximately $1,377. JAMAJAMAPolymyalgia Rheumatica and Giant Cell Arteritis

Oral glucocorticoid therapy is the standard treatment for established PMR. ScienceDirect+2ScienceDirectCurrent diagnosis and treatment of polymyalgia rheumaticaOxford AcademicFrequency, diagnosis, and management of polymyalgia ...ard eularUnderstanding the immunopathophysiology of polymyalgia ... A diagnostic-treatment approach describes prednisone 15 mg/day as the standardized initial regimen; this dose applies to suspected isolated PMR, not to patients in whom GCA remains a concern. ScienceDirectScienceDirectCurrent diagnosis and treatment of polymyalgia rheumatica

Individualize the starting plan and subsequent taper according to disease activity, laboratory markers, comorbidities, and treatment adverse events. The EULAR/ACR management recommendation strongly endorses individualized tapering with regular monitoring of all three domains. BMJBMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic Diseases This is particularly important in older adults, in whom even low-dose corticosteroids can cause clinically meaningful toxicity. rheumatologyrheumatologyPolymyalgia Rheumatica | American College of Rheumatology

For initial tapering, reduce to prednisone-equivalent 10 mg/day within 4-8 weeks. BMJBMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic Diseases Once remission is achieved, reduce by 1 mg/day every 4 weeks until discontinuation if remission is maintained; an alternative cited approach uses 1.25-mg decrements through alternating daily schedules such as 10 mg and 7.5 mg on alternate days. BMJBMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic Diseases

Treat clinical relapse by increasing prednisone to the pre-relapse dose, then gradually reducing over 4-8 weeks to the dose at which relapse occurred. BMJBMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic Diseases Do not use a rigid taper when symptoms, inflammatory markers, or adverse events argue for a different pace; the recommendation specifically prioritizes regular reassessment over a fixed schedule. BMJBMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic Diseases

At follow-up, assess clinical disease activity, repeat the laboratory markers used at baseline, and review adverse events at intervals matched to the taper. BMJBMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic Diseases A rising inflammatory marker without concordant symptoms should not by itself define relapse, but discordance between symptoms, markers, and the expected taper trajectory should trigger reassessment for an alternative diagnosis or concurrent GCA. BMJ+2BMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic DiseasesScienceDirectCurrent diagnosis and treatment of polymyalgia rheumaticaScienceDirectPolymyalgia Rheumatica - an overview

Repeat the GCA symptom screen throughout treatment: headache, visual changes, scalp tenderness, temporal artery findings, and fever remain management-changing symptoms because PMR may coexist with GCA. accessdata fda+2accessdata fda125276Orig1s112 | FDAAHA JournalsMedium- and Large-Vessel Vasculitis | CirculationrheumatologyPolymyalgia Rheumatica | American College of Rheumatology New visual symptoms or ischemic features require urgent escalation rather than adjustment of a routine PMR taper. accessdata fdaaccessdata fda125276Orig1s112 | FDA

Build glucocorticoid toxicity surveillance into every visit. The ACR patient guidance identifies hypertension, osteoporosis, weight gain, cataracts, insomnia, bruising, and skin thinning as adverse effects requiring regular check-ups, and notes that older patients may require osteoporosis medications to prevent fractures. rheumatologyrheumatologyPolymyalgia Rheumatica | American College of Rheumatology A taper that controls symptoms but produces unacceptable toxicity should be revisited using the guideline principle of individualized dosing and adverse-event monitoring. BMJ+1BMJ2015 Recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative | Annals of the Rheumatic DiseasesrheumatologyPolymyalgia Rheumatica | American College of Rheumatology

Reopen the diagnostic process when response is incomplete, relapse occurs repeatedly, inflammatory markers are atypical, or the symptom distribution becomes asymmetric or limited. PMR is not confirmed simply because symptoms transiently improve on prednisone; rheumatic disorders, infection, and malignancy can present as a polymyalgic syndrome and may declare themselves during follow-up. ScienceDirect+1ScienceDirectCurrent diagnosis and treatment of polymyalgia rheumaticaScienceDirectPolymyalgia Rheumatica - an overview